歌礼制药-B二零二三年年报

24561031355265110115116117118119121186 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 198D12 24840 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 183171712-1716 1526 108 1672 www.ascletis.com β(THRβ)ASC41NASH52IIFASNASC40IIISagimetBiosciencesF2/F3 NASHASC402bFASCINATE-2 FDAIND FXRASC42 NASH 54.14.6%56.6112.064.8%184.7166.145.2%241.2 2,274.6 267.118.8%216.8(i)(ii) NASH/PBCFDAINDIIIIIIIIIII 26.024.7(i)(ii)2.54.6%(iii) 314.8144.7(i)(ii)(iii)SagimetBiosciences (i)β(THRβ)ASC41NASH52II(ii)Sagimet BiosciencesF2/F3 NASHASC402bFASCINATE-2(iii)FASNASC40II(iv)FASNASC40III(v)FASNASC40rGBMIII120120PFS(vi)PD-L1ASC22IIb24ASC2244/1921.1%HBsAg0/60%HBsAgASC22(vii)12 1.ASC22 1CHBHIVRdRpCOVID-19 1.NASH/PBC 2.Sagimet Biosciences3-V Biosciences, Inc.ASC40 FASNTHRββFXRXNASHPBC 1.Sagimet Biosciences3-V Biosciences, Inc.ASC40 FASNVEGFPD-L11 1.Sagimet Biosciences3-V Biosciences, Inc.ASC40 FASN ASC22 ASC22IIb49HBsAg≤100IU/mL(AASLD)(The Liver Meeting®2023) ASC2249HBsAg≤100IU/mL(Q2W)1.0ASC22ASC22n=40n=94:124NAs24ASC2224HBsAgNAsHBsAg50%24ASC22ASC22NAsHBsAg2421.1%(4/19)HBsAgASC22 8,6001591NAsRNADNAcccDNARNAHBsAgASC22PD-1/PD-L1HBsAg ASC22IIb2424ASC22 1.Lim J K, Nguyen M H, Kim W R, et al.Prevalence of Chronic Hepatitis B Virus Infection in the United States J. TheAmerican journal of gastroenterology 2020, 115(9): 1429-38. RSVASC10 FDAASC10(RSV)IIa ASC10ASC10ASC10-ANHCEIDD-19311ASC10-A (NHC)HEp-2(EC50)0.510.6uM1ASC10-A (NHC) 6,400162AstuteAnalytica14.9%423 ASC10RSVIIa 1.Jeong-Joong Yoon, Mart Toots, Sujin Lee, et al.Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitorof Influenza and Respiratory Syncytial Viruses.Antimicrob Agents Chemother.2018;62(8):e00766-18.2.https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv3.https://www.astuteanalytica.com/industry-report/respiratory-syncytial-virus-market HIVASC22 12(IAS)HIVASC22HIVIIClinicalTrials.gov:NCT0512918915HIV124ASC22110ARTIIASC22HIV812CAHIVRNA4.273.41(P =0.001,P =0.006)CA HIV RNADNAP =0.038,P =0.017) IIASC224112.5ARTHIV-11212II 3,900HIV63130HIV1 ASC22ARTII 1.UNAIDS.Global HIV & AIDS statisticsFACT SHEET.2022.https://www.unaids.org/en/resources/fact-sheet ASC10ASC11 ASC10IIIASC11II IIIASC10 IIIASC11 IIIII ASC10ASC11 NASHPBC NASHASC40 SagimetBiosciences23F2/F3NASHASC40522bFASCINATE-2NASHNAS≥2NAS≥2≥1NASHMRI-PDFF≥30% 2bFASCINATE-252168NAS≥4F2F3NASH 2:150 2bASC40F2F3NASH NASHASC41 NASHASC41II MRI-PDFFASC41ASC4193.3%30%30%NASHTHRβNASHASC411268.2%12(ALT)(AST)37.8%41.5%12(LDL-C)(TC)(TG)27.7%23.4%46.5%ASC41(AE)(GI) ASC41THRβASC41ASC41 II(ClinicalTrials.gov:NCT05462353)180NASH1:1:1ASC41245244212ASC41 NASHASC41II PBCASC42 FXRASC42II98PBC 12II(ClinicalTrials.gov: NCT05190523)ASC425101598UDCA PBCASC42IIPBCASC4212IIPBCASC42 NASHASC43F ASC43F5THRβASC4115FXRASC42IClinicalTrials.govNCT05118516ASC43FASC43FASC43FASC41ASC42ASC41ASC42 I5ASC41NAFLDLDL-CNASHLDL-C(TG) IASC421514LDC-CFXRFGF1915141,780%C41491% PBCASC42IIFXRASC42(ASC43F) rGBMASC40 ASC40rGBMIII120 ASC40FASN(DNL)ASC401 IIIClinicalTrials.govNCT05118776rGBM(PFS)(OS)1801:11ASC40+2+120PFS93PFS GBMIV2GBM57%2.854.561046.4GBM3GBM56.6%3.2110490%GBMrGBM ASC40rGBMIII 1.Fhu CW, Ali A. Fatty Acid Synthase: An Emerging Target in Cancer.Molecules.2020;25(17):3935. doi:10.3390/molecules25173935.2.LouisN,Perry A,Reifenberge RG,von Deimling A,Figarella-Branger D,Cavenee WK,et al.The 2016WorldHealth Organization classification of tumors of the central nervous system:A summary.ActaNeuropathol.2016;131:803-20.3.20174.Ostrom Q T, Gittleman H, Truitt G, et al.CBTRUS Statistical Report: Primary Brain and Other Central NervousSystem Tumors Diagnosed in the United States in 2011-2015 [J].Neuro Oncol 2018, 20(suppl_4): iv1-iv86.DOI:10.1093/neuonc/noy131. ASC61 ASC61I ASC61IIII ASC61PD-L1PD-L1PD-1/PD-L1ASC61(AtezolizumabFDAPD-L1 PD-1/PD-L1PD-L1ASC61(1)(2)(3)(4)(5) ASC61I ASC40 ASC40IIIIII IIIASC404801:150ASC4012 ASC40II ASC40FASNASC40(1)(DNL)(2)Th17Sagimet BiosciencesASC40 6.4130%40%2AASC40 ASC40III 1.Tan J K, Bhate K. A global perspective on the epidemiology of acne [J].Br J Dermatol 2015, 172 Suppl 1(3-12).DOI: 10.1111/bjd.13462. 2.Purvis CG, Balogh EA, Feldman SR.Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the AcneTreatment Paradigm.Ann Pharmacother.2021;55(10):1297-1299. doi:10.1177/1060028021992055. 18A.05 17,000 11 12NASH 1.ASC41NASHII2.ASC40F2F3NASH3.ASC40III4.rGBMASC40 III5.6.7. 54.14.6%56.649.440.4® 78.830.6® Presidio 26.024.7(i)(ii)2.54.6%(iii) 112.064.8%184.7(i)SagimetBiosciences60.6(ii)44.2124.8%99.3 17.097.7%0.4®HCV 35.2228.5%115.6 (i)(ii)(iii) 267.118.8%216.8(i)(ii) 1.PBC 59.896.4%2.1 0.10.2 20.56.1 23.95.4® 3090 5.4164.4%14.3 8.149.2%4.1 1.4 11.224.8 5,000,00035,394,000 42.740.9 30.511.6%34.0 144.2258.2 149.8174.1 81.5 Viking Therapeutics, Inc.VikingASC41ASC43FVikingViking 0.21.9 (1)(2)(3)100% 23.